Author: "Fortner, Renée T." - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Fortner, Renée T."' showing total 476 results

Start Over Author "Fortner, Renée T."

476 results on '"Fortner, Renée T."'

1. Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway

Author: Støer, Nathalie C., Vangen, Siri, Singh, Deependra, Fortner, Renée T., Hofvind, Solveig, Ursin, Giske, and Botteri, Edoardo
Published: 2024
Full Text: View/download PDF

2. Recreational physical activity and breast cancer risk by menopausal status and tumor hormone receptor status: results from the Nurses’ Health Studies

Author: Fortner, Renée T., Brantley, Kristen D., Tworoger, Shelley S., Tamimi, Rulla M., Rosner, Bernard, Holmes, Michelle D., Willett, Walter C., and Eliassen, A. Heather
Published: 2024
Full Text: View/download PDF

3. Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis

Author: Fu, Zhuxuan, Brooks, Maria Mori, Irvin, Sarah, Jordan, Susan, Aben, Katja KH, Anton-Culver, Hoda, Bandera, Elisa V, Beckmann, Matthias W, Berchuck, Andrew, Brooks-Wilson, Angela, Chang-Claude, Jenny, Cook, Linda S, Cramer, Daniel W, Cushing-Haugen, Kara L, Doherty, Jennifer A, Ekici, Arif B, Fasching, Peter A, Fortner, Renée T, Gayther, Simon A, Gentry-Maharaj, Aleksandra, Giles, Graham G, Goode, Ellen L, Goodman, Marc T, Group, AOCS, Harris, Holly R, Hein, Alexander, Kaaks, Rudolf, Kiemeney, Lambertus A, Köbel, Martin, Kotsopoulos, Joanne, Le, Nhu D, Lee, Alice W, Matsuo, Keitaro, McGuire, Valerie, McLaughlin, John R, Menon, Usha, Milne, Roger L, Moysich, Kirsten B, Pearce, Celeste Leigh, Pike, Malcolm C, Qin, Bo, Ramus, Susan J, Riggan, Marjorie J, Rothstein, Joseph H, Schildkraut, Joellen M, Sieh, Weiva, Sutphen, Rebecca, Terry, Kathryn L, Thompson, Pamela J, Titus, Linda, van Altena, Anne M, White, Emily, Whittemore, Alice S, Wu, Anna H, Zheng, Wei, Ziogas, Argyrios, Taylor, Sarah E, Tang, Lu, Songer, Thomas, Wentzensen, Nicolas, Webb, Penelope M, Risch, Harvey A, and Modugno, Francesmary
Subjects: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Clinical Research, Cancer, Ovarian Cancer, Prevention, Pregnancy, Humans, Female, Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Risk Factors, Parity, Contraceptives, Oral, Case-Control Studies, AOCS Group, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract: BackgroundThe role of ovulation in epithelial ovarian cancer (EOC) is supported by the consistent protective effects of parity and oral contraceptive use. Whether these factors protect through anovulation alone remains unclear. We explored the association between lifetime ovulatory years (LOY) and EOC.MethodsLOY was calculated using 12 algorithms. Odds ratios (ORs) and 95% confidence intervals (CIs) estimated the association between LOY or LOY components and EOC among 26 204 control participants and 21 267 case patients from 25 studies. To assess whether LOY components act through ovulation suppression alone, we compared beta coefficients obtained from regression models with expected estimates assuming 1 year of ovulation suppression has the same effect regardless of source.ResultsLOY was associated with increased EOC risk (OR per year increase = 1.014, 95% CI = 1.009 to 1.020 to OR per year increase = 1.044, 95% CI = 1.041 to 1.048). Individual LOY components, except age at menarche, also associated with EOC. The estimated model coefficient for oral contraceptive use and pregnancies were 4.45 times and 12- to 15-fold greater than expected, respectively. LOY was associated with high-grade serous, low-grade serous, endometrioid, and clear cell histotypes (ORs per year increase = 1.054, 1.040, 1.065, and 1.098, respectively) but not mucinous tumors. Estimated coefficients of LOY components were close to expected estimates for high-grade serous but larger than expected for low-grade serous, endometrioid, and clear cell histotypes.ConclusionsLOY is positively associated with nonmucinous EOC. Differences between estimated and expected model coefficients for LOY components suggest factors beyond ovulation underlie the associations between LOY components and EOC in general and for non-HGSOC.
Published: 2023

4. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

Author: Köbel, Martin, Kang, Eun‐Young, Weir, Ashley, Rambau, Peter F, Lee, Cheng‐Han, Nelson, Gregg S, Ghatage, Prafull, Meagher, Nicola S, Riggan, Marjorie J, Alsop, Jennifer, Anglesio, Michael S, Beckmann, Matthias W, Bisinotto, Christiani, Boisen, Michelle, Boros, Jessica, Brand, Alison H, Brooks‐Wilson, Angela, Carney, Michael E, Coulson, Penny, Courtney‐Brooks, Madeleine, Cushing‐Haugen, Kara L, Cybulski, Cezary, Deen, Suha, El‐Bahrawy, Mona A, Elishaev, Esther, Erber, Ramona, Fereday, Sian, Group, AOCS, Fischer, Anna, Gayther, Simon A, Barquin‐Garcia, Arantzazu, Gentry‐Maharaj, Aleksandra, Gilks, C Blake, Gronwald, Helena, Grube, Marcel, Harnett, Paul R, Harris, Holly R, Hartkopf, Andreas D, Hartmann, Arndt, Hein, Alexander, Hendley, Joy, Hernandez, Brenda Y, Huang, Yajue, Jakubowska, Anna, Jimenez‐Linan, Mercedes, Jones, Michael E, Kennedy, Catherine J, Kluz, Tomasz, Koziak, Jennifer M, Lesnock, Jaime, Lester, Jenny, Lubiński, Jan, Longacre, Teri A, Lycke, Maria, Mateoiu, Constantina, McCauley, Bryan M, McGuire, Valerie, Ney, Britta, Olawaiye, Alexander, Orsulic, Sandra, Osorio, Ana, Paz‐Ares, Luis, Ramón y Cajal, Teresa, Rothstein, Joseph H, Ruebner, Matthias, Schoemaker, Minouk J, Shah, Mitul, Sharma, Raghwa, Sherman, Mark E, Shvetsov, Yurii B, Singh, Naveena, Steed, Helen, Storr, Sarah J, Talhouk, Aline, Traficante, Nadia, Wang, Chen, Whittemore, Alice S, Widschwendter, Martin, Wilkens, Lynne R, Winham, Stacey J, Benitez, Javier, Berchuck, Andrew, Bowtell, David D, dos Reis, Francisco J Candido, Campbell, Ian, Cook, Linda S, DeFazio, Anna, Doherty, Jennifer A, Fasching, Peter A, Fortner, Renée T, García, María J, Goodman, Marc T, Goode, Ellen L, Gronwald, Jacek, Huntsman, David G, Karlan, Beth Y, Kelemen, Linda E, Kommoss, Stefan, Le, Nhu D, and Martin, Stewart G
Subjects: Reproductive Medicine, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Rare Diseases, Ovarian Cancer, Clinical Research, Aetiology, 2.1 Biological and endogenous factors, Humans, Female, Tumor Suppressor Protein p53, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Carcinoma, Endometrioid, ovarian cancer, high-grade serous carcinoma, endometrioid, clear cell, TP53, p53, prognosis, AOCS Group, Clinical sciences
Abstract: Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36-3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11-2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC.
Published: 2023

5. Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia

Author: Hurwitz, Lauren M, Townsend, Mary K, Jordan, Susan J, Patel, Alpa V, Teras, Lauren R, Lacey, James V, Doherty, Jennifer A, Harris, Holly R, Goodman, Marc T, Shvetsov, Yurii B, Modugno, Francesmary, Moysich, Kirsten B, Robien, Kim, Prizment, Anna, Schildkraut, Joellen M, Berchuck, Andrew, Fortner, Renée T, Chan, Andrew T, Wentzensen, Nicolas, Hartge, Patricia, Sandler, Dale P, O'Brien, Katie M, Anton-Culver, Hoda, Ziogas, Argyrios, Menon, Usha, Ramus, Susan J, Pearce, Celeste Leigh, Wu, Anna H, White, Emily, Peters, Ulrike, Webb, Penelope M, Tworoger, Shelley S, and Trabert, Britton
Subjects: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Prevention, Cancer, Patient Safety, Clinical Research, Ovarian Cancer, Rare Diseases, Breast Cancer, 3.3 Nutrition and chemoprevention, Prevention of disease and conditions, and promotion of well-being, Female, Humans, Aspirin, Endometriosis, Ovarian Neoplasms, Case-Control Studies, Risk Factors, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract: PurposeFrequent aspirin use has been associated with reduced ovarian cancer risk, but no study has comprehensively assessed for effect modification. We leveraged harmonized, individual-level data from 17 studies to examine the association between frequent aspirin use and ovarian cancer risk, overall and across subgroups of women with other ovarian cancer risk factors.MethodsNine cohort studies from the Ovarian Cancer Cohort Consortium (n = 2,600 cases) and eight case-control studies from the Ovarian Cancer Association Consortium (n = 5,726 cases) were included. We used Cox regression and logistic regression to assess study-specific associations between frequent aspirin use (≥ 6 days/week) and ovarian cancer risk and combined study-specific estimates using random-effects meta-analysis. We conducted analyses within subgroups defined by individual ovarian cancer risk factors (endometriosis, obesity, family history of breast/ovarian cancer, nulliparity, oral contraceptive use, and tubal ligation) and by number of risk factors (0, 1, and ≥ 2).ResultsOverall, frequent aspirin use was associated with a 13% reduction in ovarian cancer risk (95% CI, 6 to 20), with no significant heterogeneity by study design (P = .48) or histotype (P = .60). Although no association was observed among women with endometriosis, consistent risk reductions were observed among all other subgroups defined by ovarian cancer risk factors (relative risks ranging from 0.79 to 0.93, all P-heterogeneity > .05), including women with ≥ 2 risk factors (relative risk, 0.81; 95% CI, 0.73 to 0.90).ConclusionThis study, the largest to-date on aspirin use and ovarian cancer, provides evidence that frequent aspirin use is associated with lower ovarian cancer risk regardless of the presence of most other ovarian cancer risk factors. Risk reductions were also observed among women with multiple risk factors, providing proof of principle that chemoprevention programs with frequent aspirin use could target higher-risk subgroups.
Published: 2022

6. Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci

Author: DeVries, Amber A, Dennis, Joe, Tyrer, Jonathan P, Peng, Pei-Chen, Coetzee, Simon G, Reyes, Alberto L, Plummer, Jasmine T, Davis, Brian D, Chen, Stephanie S, Dezem, Felipe Segato, Aben, Katja KH, Anton-Culver, Hoda, Antonenkova, Natalia N, Beckmann, Matthias W, Beeghly-Fadiel, Alicia, Berchuck, Andrew, Bogdanova, Natalia V, Bogdanova-Markov, Nadja, Brenton, James D, Butzow, Ralf, Campbell, Ian, Chang-Claude, Jenny, Chenevix-Trench, Georgia, Cook, Linda S, DeFazio, Anna, Doherty, Jennifer A, Dörk, Thilo, Eccles, Diana M, Eliassen, A Heather, Fasching, Peter A, Fortner, Renée T, Giles, Graham G, Goode, Ellen L, Goodman, Marc T, Gronwald, Jacek, Webb, P, DeFazio, A, Friedlander, M, Obermair, A, Grant, P, Nagle, C, Beesley, V, Chevenix-Trench, G, Bowtell, D, Blomfield, P, Brand, A, Davis, A, Leung, Y, Nicklin, J, Quinn, M, Livingstone, K, O'Neill, H, Williams, M, Black, A, Hadley, A, Glasgow, A, Garrett, A, Rao, A, Shannon, C, Steer, C, Allen, D, Neesham, D, Otton, G, Au-Yeung, G, Goss, G, Wain, G, Gard, G, Robertson, G, Lombard, J, Tan, J, McNeilage, J, Power, J, Coward, J, Miller, J, Carter, J, Lamont, J, Wong, KM, Reid, K, Perrin, L, Milishkin, L, Nascimento, M, Buck, M, Bunting, M, Harrison, M, Chetty, N, Hacker, N, McNally, O, Harnett, P, Beale, P, Awad, R, Mohan, R, Farrell, R, McIntosh, R, Rome, R, Sayer, R, Houghton, R, Hogg, R, Land, R, Baron-Hay, S, and Paramasivum, S
Subjects: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Genetics, Human Genome, Cancer, Prevention, Rare Diseases, Ovarian Cancer, Genetic Testing, Aetiology, 2.1 Biological and endogenous factors, Female, Humans, Carcinoma, Ovarian Epithelial, Genome-Wide Association Study, Alleles, DNA Copy Number Variations, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Ovarian Neoplasms, OPAL Study Group, AOCS Group, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract: BackgroundKnown risk alleles for epithelial ovarian cancer (EOC) account for approximately 40% of the heritability for EOC. Copy number variants (CNVs) have not been investigated as EOC risk alleles in a large population cohort.MethodsSingle nucleotide polymorphism array data from 13 071 EOC cases and 17 306 controls of White European ancestry were used to identify CNVs associated with EOC risk using a rare admixture maximum likelihood test for gene burden and a by-probe ratio test. We performed enrichment analysis of CNVs at known EOC risk loci and functional biofeatures in ovarian cancer-related cell types.ResultsWe identified statistically significant risk associations with CNVs at known EOC risk genes; BRCA1 (PEOC = 1.60E-21; OREOC = 8.24), RAD51C (Phigh-grade serous ovarian cancer [HGSOC] = 5.5E-4; odds ratio [OR]HGSOC = 5.74 del), and BRCA2 (PHGSOC = 7.0E-4; ORHGSOC = 3.31 deletion). Four suggestive associations (P
Published: 2022

7. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk

Author: Dareng, Eileen O, Tyrer, Jonathan P, Barnes, Daniel R, Jones, Michelle R, Yang, Xin, Aben, Katja KH, Adank, Muriel A, Agata, Simona, Andrulis, Irene L, Anton-Culver, Hoda, Antonenkova, Natalia N, Aravantinos, Gerasimos, Arun, Banu K, Augustinsson, Annelie, Balmaña, Judith, Bandera, Elisa V, Barkardottir, Rosa B, Barrowdale, Daniel, Beckmann, Matthias W, Beeghly-Fadiel, Alicia, Benitez, Javier, Bermisheva, Marina, Bernardini, Marcus Q, Bjorge, Line, Black, Amanda, Bogdanova, Natalia V, Bonanni, Bernardo, Borg, Ake, Brenton, James D, Budzilowska, Agnieszka, Butzow, Ralf, Buys, Saundra S, Cai, Hui, Caligo, Maria A, Campbell, Ian, Cannioto, Rikki, Cassingham, Hayley, Chang-Claude, Jenny, Chanock, Stephen J, Chen, Kexin, Chiew, Yoke-Eng, Chung, Wendy K, Claes, Kathleen BM, Colonna, Sarah, Cook, Linda S, Couch, Fergus J, Daly, Mary B, Dao, Fanny, Davies, Eleanor, de la Hoya, Miguel, de Putter, Robin, Dennis, Joe, DePersia, Allison, Devilee, Peter, Diez, Orland, Ding, Yuan Chun, Doherty, Jennifer A, Domchek, Susan M, Dörk, Thilo, du Bois, Andreas, Dürst, Matthias, Eccles, Diana M, Eliassen, Heather A, Engel, Christoph, Evans, Gareth D, Fasching, Peter A, Flanagan, James M, Fortner, Renée T, Machackova, Eva, Friedman, Eitan, Ganz, Patricia A, Garber, Judy, Gensini, Francesca, Giles, Graham G, Glendon, Gord, Godwin, Andrew K, Goodman, Marc T, Greene, Mark H, Gronwald, Jacek, Hahnen, Eric, Haiman, Christopher A, Håkansson, Niclas, Hamann, Ute, Hansen, Thomas VO, Harris, Holly R, Hartman, Mikael, Heitz, Florian, Hildebrandt, Michelle AT, Høgdall, Estrid, Høgdall, Claus K, Hopper, John L, Huang, Ruea-Yea, Huff, Chad, Hulick, Peter J, Huntsman, David G, Imyanitov, Evgeny N, Isaacs, Claudine, Jakubowska, Anna, James, Paul A, and Janavicius, Ramunas
Subjects: GEMO Study Collaborators, GC-HBOC Study Collaborators, EMBRACE Collaborators, OPAL Study Group, AOCS Group, KConFab Investigators, HEBON Investigators, OCAC Consortium, CIMBA Consortium, Genetics, Clinical Sciences, Genetics & Heredity
Published: 2022

8. Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions

Author: Dareng, Eileen O., Coetzee, Simon G., Tyrer, Jonathan P., Peng, Pei-Chen, Rosenow, Will, Chen, Stephanie, Davis, Brian D., Dezem, Felipe Segato, Seo, Ji-Heui, Nameki, Robbin, Reyes, Alberto L., Aben, Katja K.H., Anton-Culver, Hoda, Antonenkova, Natalia N., Aravantinos, Gerasimos, Bandera, Elisa V., Beane Freeman, Laura E., Beckmann, Matthias W., Beeghly-Fadiel, Alicia, Benitez, Javier, Bernardini, Marcus Q., Bjorge, Line, Black, Amanda, Bogdanova, Natalia V., Bolton, Kelly L., Brenton, James D., Budzilowska, Agnieszka, Butzow, Ralf, Cai, Hui, Campbell, Ian, Cannioto, Rikki, Chang-Claude, Jenny, Chanock, Stephen J., Chen, Kexin, Chenevix-Trench, Georgia, Chiew, Yoke-Eng, Cook, Linda S., DeFazio, Anna, Dennis, Joe, Doherty, Jennifer A., Dörk, Thilo, du Bois, Andreas, Dürst, Matthias, Eccles, Diana M., Ene, Gabrielle, Fasching, Peter A., Flanagan, James M., Fortner, Renée T., Fostira, Florentia, Gentry-Maharaj, Aleksandra, Giles, Graham G., Goodman, Marc T., Gronwald, Jacek, Haiman, Christopher A., Håkansson, Niclas, Heitz, Florian, Hildebrandt, Michelle A.T., Høgdall, Estrid, Høgdall, Claus K., Huang, Ruea-Yea, Jensen, Allan, Jones, Michael E., Kang, Daehee, Karlan, Beth Y., Karnezis, Anthony N., Kelemen, Linda E., Kennedy, Catherine J., Khusnutdinova, Elza K., Kiemeney, Lambertus A., Kjaer, Susanne K., Kupryjanczyk, Jolanta, Labrie, Marilyne, Lambrechts, Diether, Larson, Melissa C., Le, Nhu D., Lester, Jenny, Li, Lian, Lubiński, Jan, Lush, Michael, Marks, Jeffrey R., Matsuo, Keitaro, May, Taymaa, McLaughlin, John R., McNeish, Iain A., Menon, Usha, Missmer, Stacey, Modugno, Francesmary, Moffitt, Melissa, Monteiro, Alvaro N., Moysich, Kirsten B., Narod, Steven A., Nguyen-Dumont, Tu, Odunsi, Kunle, Olsson, Håkan, Onland-Moret, N. Charlotte, Park, Sue K., Pejovic, Tanja, Permuth, Jennifer B., Piskorz, Anna, Prokofyeva, Darya, Riggan, Marjorie J., Risch, Harvey A., Rodríguez-Antona, Cristina, Rossing, Mary Anne, Sandler, Dale P., Setiawan, V. Wendy, Shan, Kang, Song, Honglin, Southey, Melissa C., Steed, Helen, Sutphen, Rebecca, Swerdlow, Anthony J., Teo, Soo Hwang, Terry, Kathryn L., Thompson, Pamela J., Vestrheim Thomsen, Liv Cecilie, Titus, Linda, Trabert, Britton, Travis, Ruth, Tworoger, Shelley S., Valen, Ellen, Van Nieuwenhuysen, Els, Edwards, Digna Velez, Vierkant, Robert A., Webb, Penelope M., Weinberg, Clarice R., Weise, Rayna Matsuno, Wentzensen, Nicolas, White, Emily, Winham, Stacey J., Wolk, Alicja, Woo, Yin-Ling, Wu, Anna H., Yan, Li, Yannoukakos, Drakoulis, Zeinomar, Nur, Zheng, Wei, Ziogas, Argyrios, Berchuck, Andrew, Goode, Ellen L., Huntsman, David G., Pearce, Celeste L., Ramus, Susan J., Sellers, Thomas A., Freedman, Matthew L., Lawrenson, Kate, Schildkraut, Joellen M., Hazelett, Dennis, Plummer, Jasmine T., Kar, Siddhartha, Jones, Michelle R., Pharoah, Paul D.P., and Gayther, Simon A.
Published: 2024
Full Text: View/download PDF

9. Postdiagnosis circulating osteoprotegerin and TRAIL concentrations and survival and recurrence after a breast cancer diagnosis: results from the MARIE patient cohort

Author: Le Cornet, Charlotte, Jung, Audrey Y., Johnson, Theron S., Behrens, Sabine, Obi, Nadia, Becher, Heiko, Chang-Claude, Jenny, and Fortner, Renée T.
Published: 2023
Full Text: View/download PDF

10. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

Author: Dareng, Eileen O, Tyrer, Jonathan P, Barnes, Daniel R, Jones, Michelle R, Yang, Xin, Aben, Katja KH, Adank, Muriel A, Agata, Simona, Andrulis, Irene L, Anton-Culver, Hoda, Antonenkova, Natalia N, Aravantinos, Gerasimos, Arun, Banu K, Augustinsson, Annelie, Balmaña, Judith, Bandera, Elisa V, Barkardottir, Rosa B, Barrowdale, Daniel, Beckmann, Matthias W, Beeghly-Fadiel, Alicia, Benitez, Javier, Bermisheva, Marina, Bernardini, Marcus Q, Bjorge, Line, Black, Amanda, Bogdanova, Natalia V, Bonanni, Bernardo, Borg, Ake, Brenton, James D, Budzilowska, Agnieszka, Butzow, Ralf, Buys, Saundra S, Cai, Hui, Caligo, Maria A, Campbell, Ian, Cannioto, Rikki, Cassingham, Hayley, Chang-Claude, Jenny, Chanock, Stephen J, Chen, Kexin, Chiew, Yoke-Eng, Chung, Wendy K, Claes, Kathleen BM, Colonna, Sarah, Cook, Linda S, Couch, Fergus J, Daly, Mary B, Dao, Fanny, Davies, Eleanor, de la Hoya, Miguel, de Putter, Robin, Dennis, Joe, DePersia, Allison, Devilee, Peter, Diez, Orland, Ding, Yuan Chun, Doherty, Jennifer A, Domchek, Susan M, Dörk, Thilo, du Bois, Andreas, Dürst, Matthias, Eccles, Diana M, Eliassen, Heather A, Engel, Christoph, Evans, Gareth D, Fasching, Peter A, Flanagan, James M, Fortner, Renée T, Machackova, Eva, Friedman, Eitan, Ganz, Patricia A, Garber, Judy, Gensini, Francesca, Giles, Graham G, Glendon, Gord, Godwin, Andrew K, Goodman, Marc T, Greene, Mark H, Gronwald, Jacek, Hahnen, Eric, Haiman, Christopher A, Håkansson, Niclas, Hamann, Ute, Hansen, Thomas VO, Harris, Holly R, Hartman, Mikael, Heitz, Florian, Hildebrandt, Michelle AT, Høgdall, Estrid, Høgdall, Claus K, Hopper, John L, Huang, Ruea-Yea, Huff, Chad, Hulick, Peter J, Huntsman, David G, Imyanitov, Evgeny N, Isaacs, Claudine, Jakubowska, Anna, James, Paul A, and Janavicius, Ramunas
Subjects: Prevention, Cancer, Ovarian Cancer, Rare Diseases, Good Health and Well Being, Bayes Theorem, Breast Neoplasms, Carcinoma, Ovarian Epithelial, Female, Genetic Predisposition to Disease, Humans, Male, Ovarian Neoplasms, Polymorphism, Single Nucleotide, Prospective Studies, Risk Factors, GEMO Study Collaborators, GC-HBOC Study Collaborators, EMBRACE Collaborators, OPAL Study Group, AOCS Group, KConFab Investigators, HEBON Investigators, OCAC Consortium, CIMBA Consortium, Genetics, Clinical Sciences, Genetics & Heredity
Abstract: Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented computationally efficient, penalized, logistic regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, "select and shrink for summary statistics" (S4), to summary level data for epithelial non-mucinous ovarian cancer risk prediction. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries: prospective data from 198,101 women of European ancestries; 7,669 women of East Asian ancestries; 1,072 women of African ancestries, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestries. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38 (95% CI: 1.28-1.48, AUC: 0.588) per unit standard deviation, in women of European ancestries; 1.14 (95% CI: 1.08-1.19, AUC: 0.538) in women of East Asian ancestries; 1.38 (95% CI: 1.21-1.58, AUC: 0.593) in women of African ancestries; hazard ratios of 1.36 (95% CI: 1.29-1.43, AUC: 0.592) in BRCA1 pathogenic variant carriers and 1.49 (95% CI: 1.35-1.64, AUC: 0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs.
Published: 2022

11. Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association

Author: Khoja, Lilah, Weber, Rachel Palmieri, Group, The Australian Ovarian Cancer Study, Webb, Penelope M, Jordan, Susan J, Muthukumar, Aruna, Chang-Claude, Jenny, Fortner, Renée T, Jensen, Allan, Kjaer, Susanne K, Risch, Harvey, Doherty, Jennifer Anne, Harris, Holly R, Goodman, Marc T, Modugno, Francesmary, Moysich, Kirsten, Berchuck, Andrew, Schildkraut, Joellen M, Cramer, Daniel, Terry, Kathryn L, Anton-Culver, Hoda, Ziogas, Argyrios, Phung, Minh Tung, Hanley, Gillian E, Wu, Anna H, Mukherjee, Bhramar, McLean, Karen, Cho, Kathleen, Pike, Malcolm C, Pearce, Celeste Leigh, and Lee, Alice W
Subjects: Reproductive Medicine, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Endometriosis, Ovarian Cancer, Rare Diseases, Contraception/Reproduction, Clinical Research, Estrogen, 2.1 Biological and endogenous factors, Aetiology, Case-Control Studies, Estrogen Replacement Therapy, Female, Humans, Hysterectomy, Menopause, Ovarian Neoplasms, Ovarian cancer, Hormone therapy, Australian Ovarian Cancer Study Group, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Abstract: ObjectiveTo evaluate the association between hysterectomy and ovarian cancer, and to understand how hormone therapy (HT) use and endometriosis affect this association.MethodsWe conducted a pooled analysis of self-reported data from 11 case-control studies in the Ovarian Cancer Association Consortium (OCAC). Women with (n = 5350) and without ovarian cancer (n = 7544) who never used HT or exclusively used either estrogen-only therapy (ET) or estrogen+progestin therapy (EPT) were included. Risk of invasive epithelial ovarian cancer adjusted for duration of ET and EPT use and stratified on history of endometriosis was determined using odds ratios (ORs) with 95% confidence intervals (CIs).ResultsOverall and among women without endometriosis, there was a positive association between ovarian cancer risk and hysterectomy (OR = 1.19, 95% CI 1.09-1.31 and OR = 1.20, 95% CI 1.09-1.32, respectively), but no association upon adjusting for duration of ET and EPT use (OR = 1.04, 95% CI 0.94-1.16 and OR = 1.06, 95% CI 0.95-1.18, respectively). Among women with a history of endometriosis, there was a slight inverse association between hysterectomy and ovarian cancer risk (OR = 0.93, 95% CI 0.69-1.26), but this association became stronger and statistically significant after adjusting for duration of ET and EPT use (OR = 0.69, 95% CI 0.48-0.99).ConclusionsThe hysterectomy-ovarian cancer association is complex and cannot be understood without considering duration of ET and EPT use and history of endometriosis. Failure to take these exposures into account in prior studies casts doubt on their conclusions. Overall, hysterectomy is not risk-reducing for ovarian cancer, however the inverse association among women with endometriosis warrants further investigation.
Published: 2022

12. The association between body fatness and mortality among breast cancer survivors: results from a prospective cohort study

Author: Bonet, Catalina, Crous-Bou, Marta, Tsilidis, Konstantinos K., Gunter, Marc J., Kaaks, Rudolf, Schulze, Matthias B., Fortner, Renée T., Antoniussen, Christian S., Dahm, Christina C., Mellemkjær, Lene, Tjønneland, Anne, Amiano, Pilar, Ardanaz, Eva, Colorado-Yohar, Sandra M., Rodriguez-Barranco, Miguel, Tin Tin, Sandar, Agnoli, Claudia, Masala, Giovanna, Panico, Salvatore, Sacerdote, Carlotta, May, Anne M., Borch, Kristin Benjaminsen, Rylander, Charlotta, Skeie, Guri, Christakoudi, Sofia, Aune, Dagfinn, Weiderpass, Elisabete, Dossus, Laure, Riboli, Elio, and Agudo, Antonio
Published: 2023
Full Text: View/download PDF

13. Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)

Author: Talhouk, Aline, George, Joshy, Wang, Chen, Budden, Timothy, Tan, Tuan Zea, Chiu, Derek S, Kommoss, Stefan, San Leong, Huei, Chen, Stephanie, Intermaggio, Maria P, Gilks, Blake, Nazeran, Tayyebeh M, Volchek, Mila, Elatre, Wafaa, Bentley, Rex C, Senz, Janine, Lum, Amy, Chow, Veronica, Sudderuddin, Hanwei, Mackenzie, Robertson, Leong, Samuel CY, Liu, Geyi, Johnson, Dustin, Chen, Billy, Group, AOCS, Alsop, Jennifer, Banerjee, Susana N, Behrens, Sabine, Bodelon, Clara, Brand, Alison H, Brinton, Louise, Carney, Michael E, Chiew, Yoke-Eng, Cushing-Haugen, Kara L, Cybulski, Cezary, Ennis, Darren, Fereday, Sian, Fortner, Renée T, García-Donas, Jesús, Gentry-Maharaj, Aleksandra, Glasspool, Rosalind, Goranova, Teodora, Greene, Casey S, Haluska, Paul, Harris, Holly R, Hendley, Joy, Hernandez, Brenda Y, Herpel, Esther, Jimenez-Linan, Mercedes, Karpinskyj, Chloe, Kaufmann, Scott H, Keeney, Gary L, Kennedy, Catherine J, Köbel, Martin, Koziak, Jennifer M, Larson, Melissa C, Lester, Jenny, Lewsley, Liz-Anne, Lissowska, Jolanta, Lubiński, Jan, Luk, Hugh, Macintyre, Geoff, Mahner, Sven, McNeish, Iain A, Menkiszak, Janusz, Nevins, Nikilyn, Osorio, Ana, Oszurek, Oleg, Palacios, José, Hinsley, Samantha, Pearce, Celeste L, Pike, Malcolm C, Piskorz, Anna M, Ray-Coquard, Isabelle, Rhenius, Valerie, Rodriguez-Antona, Cristina, Sharma, Raghwa, Sherman, Mark E, De Silva, Dilrini, Singh, Naveena, Sinn, Peter, Slamon, Dennis, Song, Honglin, Steed, Helen, Stronach, Euan A, Thompson, Pamela J, Tołoczko, Aleksandra, Trabert, Britton, Traficante, Nadia, Tseng, Chiu-Chen, Widschwendter, Martin, Wilkens, Lynne R, Winham, Stacey J, Winterhoff, Boris, Beeghly-Fadiel, Alicia, Benitez, Javier, Berchuck, Andrew, Brenton, James D, Brown, Robert, and Chang-Claude, Jenny
Subjects: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Orphan Drug, Genetics, Ovarian Cancer, Women's Health, Cancer Genomics, Precision Medicine, Cancer, Human Genome, 4.2 Evaluation of markers and technologies, Good Health and Well Being, Aged, Algorithms, Cystadenoma, Serous, Female, Gene Expression Regulation, Neoplastic, Humans, Lymphocytes, Tumor-Infiltrating, Middle Aged, Neoplasm Grading, Neoplasm Proteins, Neoplasm, Residual, Ovarian Neoplasms, Transcriptome, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract: PurposeGene expression-based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, evaluation of clinical utility has been hindered by nonstandardized methods, which are not applicable in a clinical setting. We sought to generate a clinical grade minimal gene set assay for classification of individual tumor specimens into HGSOC subtypes and confirm previously reported subtype-associated features.Experimental designAdopting two independent approaches, we derived and internally validated algorithms for subtype prediction using published gene expression data from 1,650 tumors. We applied resulting models to NanoString data on 3,829 HGSOCs from the Ovarian Tumor Tissue Analysis consortium. We further developed, confirmed, and validated a reduced, minimal gene set predictor, with methods suitable for a single-patient setting.ResultsGene expression data were used to derive the predictor of high-grade serous ovarian carcinoma molecular subtype (PrOTYPE) assay. We established a de facto standard as a consensus of two parallel approaches. PrOTYPE subtypes are significantly associated with age, stage, residual disease, tumor-infiltrating lymphocytes, and outcome. The locked-down clinical grade PrOTYPE test includes a model with 55 genes that predicted gene expression subtype with >95% accuracy that was maintained in all analytic and biological validations.ConclusionsWe validated the PrOTYPE assay following the Institute of Medicine guidelines for the development of omics-based tests. This fully defined and locked-down clinical grade assay will enable trial design with molecular subtype stratification and allow for objective assessment of the predictive value of HGSOC molecular subtypes in precision medicine applications.See related commentary by McMullen et al., p. 5271.
Published: 2020

14. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival

Author: Brieger, Katharine K, Peterson, Siri, Lee, Alice W, Mukherjee, Bhramar, Bakulski, Kelly M, Alimujiang, Aliya, Anton-Culver, Hoda, Anglesio, Michael S, Bandera, Elisa V, Berchuck, Andrew, Bowtell, David DL, Chenevix-Trench, Georgia, Cho, Kathleen R, Cramer, Daniel W, DeFazio, Anna, Doherty, Jennifer A, Fortner, Renée T, Garsed, Dale W, Gayther, Simon A, Gentry-Maharaj, Aleksandra, Goode, Ellen L, Goodman, Marc T, Harris, Holly R, Høgdall, Estrid, Huntsman, David G, Shen, Hui, Jensen, Allan, Johnatty, Sharon E, Jordan, Susan J, Kjaer, Susanne K, Kupryjanczyk, Jolanta, Lambrechts, Diether, McLean, Karen, Menon, Usha, Modugno, Francesmary, Moysich, Kirsten, Ness, Roberta, Ramus, Susan J, Richardson, Jean, Risch, Harvey, Rossing, Mary Anne, Trabert, Britton, Wentzensen, Nicolas, Ziogas, Argyrios, Terry, Kathryn L, Wu, Anna H, Hanley, Gillian E, Pharoah, Paul, Webb, Penelope M, Pike, Malcolm C, Pearce, Celeste Leigh, and Consortium, for the Ovarian Cancer Association
Subjects: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Estrogen, Rare Diseases, Cancer, Ovarian Cancer, Aging, Aged, Estrogen Replacement Therapy, Female, Hormone Replacement Therapy, Humans, Middle Aged, Neoplasm Staging, Neoplasm, Residual, Ovarian Neoplasms, Postmenopause, Progestins, Progression-Free Survival, Proportional Hazards Models, Survival Rate, Ovarian Cancer Association Consortium, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Abstract: PurposePrior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limited by lack of hormone regimen detail and insufficient sample sizes. To address these limitations, a comprehensive analysis of 6419 post-menopausal women with pathologically confirmed ovarian carcinoma was conducted to examine the association between MHT use prior to diagnosis and survival.MethodsData from 15 studies in the Ovarian Cancer Association Consortium were included. MHT use was examined by type (estrogen-only (ET) or estrogen+progestin (EPT)), duration, and recency of use relative to diagnosis. Cox proportional hazards models were used to estimate the association between hormone therapy use and survival. Logistic regression and mediation analysis was used to explore the relationship between MHT use and residual disease following debulking surgery.ResultsUse of ET or EPT for at least five years prior to diagnosis was associated with better ovarian cancer survival (hazard ratio, 0.80; 95% CI, 0.74 to 0.87). Among women with advanced stage, high-grade serous carcinoma, those who used MHT were less likely to have any macroscopic residual disease at the time of primary debulking surgery (p for trend
Published: 2020

15. Publisher Correction: Shared heritability and functional enrichment across six solid cancers.

Author: Jiang, Xia, Finucane, Hilary K, Schumacher, Fredrick R, Schmit, Stephanie L, Tyrer, Jonathan P, Han, Younghun, Michailidou, Kyriaki, Lesseur, Corina, Kuchenbaecker, Karoline B, Dennis, Joe, Conti, David V, Casey, Graham, Gaudet, Mia M, Huyghe, Jeroen R, Albanes, Demetrius, Aldrich, Melinda C, Andrew, Angeline S, Andrulis, Irene L, Anton-Culver, Hoda, Antoniou, Antonis C, Antonenkova, Natalia N, Arnold, Susanne M, Aronson, Kristan J, Arun, Banu K, Bandera, Elisa V, Barkardottir, Rosa B, Barnes, Daniel R, Batra, Jyotsna, Beckmann, Matthias W, Benitez, Javier, Benlloch, Sara, Berchuck, Andrew, Berndt, Sonja I, Bickeböller, Heike, Bien, Stephanie A, Blomqvist, Carl, Boccia, Stefania, Bogdanova, Natalia V, Bojesen, Stig E, Bolla, Manjeet K, Brauch, Hiltrud, Brenner, Hermann, Brenton, James D, Brook, Mark N, Brunet, Joan, Brunnström, Hans, Buchanan, Daniel D, Burwinkel, Barbara, Butzow, Ralf, Cadoni, Gabriella, Caldés, Trinidad, Caligo, Maria A, Campbell, Ian, Campbell, Peter T, Cancel-Tassin, Géraldine, Cannon-Albright, Lisa, Campa, Daniele, Caporaso, Neil, Carvalho, André L, Chan, Andrew T, Chang-Claude, Jenny, Chanock, Stephen J, Chen, Chu, Christiani, David C, Claes, Kathleen BM, Claessens, Frank, Clements, Judith, Collée, J Margriet, Correa, Marcia Cruz, Couch, Fergus J, Cox, Angela, Cunningham, Julie M, Cybulski, Cezary, Czene, Kamila, Daly, Mary B, deFazio, Anna, Devilee, Peter, Diez, Orland, Gago-Dominguez, Manuela, Donovan, Jenny L, Dörk, Thilo, Duell, Eric J, Dunning, Alison M, Dwek, Miriam, Eccles, Diana M, Edlund, Christopher K, Edwards, Digna R Velez, Ellberg, Carolina, Evans, D Gareth, Fasching, Peter A, Ferris, Robert L, Liloglou, Triantafillos, Figueiredo, Jane C, Fletcher, Olivia, Fortner, Renée T, Fostira, Florentia, Franceschi, Silvia, Friedman, Eitan, Gallinger, Steven J, and Ganz, Patricia A
Subjects: MD Multidisciplinary
Abstract: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Published: 2019

16. A comprehensive gene–environment interaction analysis in Ovarian Cancer using genome‐wide significant common variants

Author: Kim, Sehee, Wang, Miao, Tyrer, Jonathan P, Jensen, Allan, Wiensch, Ashley, Liu, Gang, Lee, Alice W, Ness, Roberta B, Salvatore, Maxwell, Tworoger, Shelley S, Whittemore, Alice S, Anton‐Culver, Hoda, Sieh, Weiva, Olson, Sara H, Berchuck, Andrew, Goode, Ellen L, Goodman, Marc T, Doherty, Jennifer Anne, Chenevix‐Trench, Georgia, Rossing, Mary Anne, Webb, Penelope M, Giles, Graham G, Terry, Kathryn L, Ziogas, Argyrios, Fortner, Renée T, Menon, Usha, Gayther, Simon A, Wu, Anna H, Song, Honglin, Brooks‐Wilson, Angela, Bandera, Elisa V, Cook, Linda S, Cramer, Daniel W, Milne, Roger L, Winham, Stacey J, Kjaer, Susanne K, Modugno, Francesmary, Thompson, Pamela J, Chang‐Claude, Jenny, Harris, Holly R, Schildkraut, Joellen M, Le, Nhu D, Wentzensen, Nico, Trabert, Britton, Høgdall, Estrid, Huntsman, David, Pike, Malcolm C, Pharoah, Paul DP, Pearce, Celeste Leigh, and Mukherjee, Bhramar
Subjects: Rare Diseases, Human Genome, Clinical Research, Genetics, Patient Safety, Cancer, Prevention, Ovarian Cancer, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Case-Control Studies, Contraceptives, Oral, Hormonal, Environment, Environmental Exposure, Female, Gene-Environment Interaction, Genetic Predisposition to Disease, Genome-Wide Association Study, Genotype, Humans, Ovarian Neoplasms, Polymorphism, Single Nucleotide, Risk, ovarian cancer, genetics, additive interaction, G x E, G × E, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract: As a follow-up to genome-wide association analysis of common variants associated with ovarian carcinoma (cancer), our study considers seven well-known ovarian cancer risk factors and their interactions with 28 genome-wide significant common genetic variants. The interaction analyses were based on data from 9971 ovarian cancer cases and 15,566 controls from 17 case-control studies. Likelihood ratio and Wald tests for multiplicative interaction and for relative excess risk due to additive interaction were used. The top multiplicative interaction was noted between oral contraceptive pill (OCP) use (ever vs. never) and rs13255292 (p value = 3.48 × 10-4 ). Among women with the TT genotype for this variant, the odds ratio for OCP use was 0.53 (95% CI = 0.46-0.60) compared to 0.71 (95%CI = 0.66-0.77) for women with the CC genotype. When stratified by duration of OCP use, women with 1-5 years of OCP use exhibited differential protective benefit across genotypes. However, no interaction on either the multiplicative or additive scale was found to be statistically significant after multiple testing correction. The results suggest that OCP use may offer increased benefit for women who are carriers of the T allele in rs13255292. On the other hand, for women carrying the C allele in this variant, longer (5+ years) use of OCP may reduce the impact of carrying the risk allele of this SNP. Replication of this finding is needed. The study presents a comprehensive analytic framework for conducting gene-environment analysis in ovarian cancer.
Published: 2019

17. Genetic data from nearly 63,000 women of European descent predicts DNA methylation biomarkers and epithelial ovarian cancer risk

Author: Yang, Yaohua, Wu, Lang, Shu, Xiang, Lu, Yingchang, Shu, Xiao-Ou, Cai, Qiuyin, Beeghly-Fadiel, Alicia, Li, Bingshan, Ye, Fei, Berchuck, Andrew, Anton-Culver, Hoda, Banerjee, Susana, Benitez, Javier, Bjørge, Line, Brenton, James D, Butzow, Ralf, Campbell, Ian G, Chang-Claude, Jenny, Chen, Kexin, Cook, Linda S, Cramer, Daniel W, deFazio, Anna, Dennis, Joe, Doherty, Jennifer A, Dörk, Thilo, Eccles, Diana M, Edwards, Digna Velez, Fasching, Peter A, Fortner, Renée T, Gayther, Simon A, Giles, Graham G, Glasspool, Rosalind M, Goode, Ellen L, Goodman, Marc T, Gronwald, Jacek, Harris, Holly R, Heitz, Florian, Hildebrandt, Michelle A, Høgdall, Estrid, Høgdall, Claus K, Huntsman, David G, Kar, Siddhartha P, Karlan, Beth Y, Kelemen, Linda E, Kiemeney, Lambertus A, Kjaer, Susanne K, Koushik, Anita, Lambrechts, Diether, Le, Nhu D, Levine, Douglas A, Massuger, Leon F, Matsuo, Keitaro, May, Taymaa, McNeish, Iain A, Menon, Usha, Modugno, Francesmary, Monteiro, Alvaro N, Moorman, Patricia G, Moysich, Kirsten B, Ness, Roberta B, Nevanlinna, Heli, Olsson, Håkan, Onland-Moret, N Charlotte, Park, Sue K, Paul, James, Pearce, Celeste L, Pejovic, Tanja, Phelan, Catherine M, Pike, Malcolm C, Ramus, Susan J, Riboli, Elio, Rodriguez-Antona, Cristina, Romieu, Isabelle, Sandler, Dale P, Schildkraut, Joellen M, Setiawan, Veronica W, Shan, Kang, Siddiqui, Nadeem, Sieh, Weiva, Stampfer, Meir J, Sutphen, Rebecca, Swerdlow, Anthony J, Szafron, Lukasz M, Teo, Soo Hwang, Tworoger, Shelley S, Tyrer, Jonathan P, Webb, Penelope M, Wentzensen, Nicolas, White, Emily, Willett, Walter C, Wolk, Alicja, Woo, Yin Ling, Wu, Anna H, Yan, Li, Yannoukakos, Drakoulis, Chenevix-Trench, Georgia, Sellers, Thomas A, Pharoah, Paul DP, Zheng, Wei, and Long, Jirong
Subjects: Biological Sciences, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Genetics, Human Genome, Ovarian Cancer, Prevention, Clinical Research, Rare Diseases, Cancer, Aetiology, 2.1 Biological and endogenous factors, Biomarkers, Tumor, Carcinoma, Ovarian Epithelial, Cohort Studies, DNA Methylation, Female, Genetic Predisposition to Disease, Humans, Models, Genetic, Ovarian Neoplasms, Predictive Value of Tests, Risk, White People, Women's Health, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract: DNA methylation is instrumental for gene regulation. Global changes in the epigenetic landscape have been recognized as a hallmark of cancer. However, the role of DNA methylation in epithelial ovarian cancer (EOC) remains unclear. In this study, high-density genetic and DNA methylation data in white blood cells from the Framingham Heart Study (N = 1,595) were used to build genetic models to predict DNA methylation levels. These prediction models were then applied to the summary statistics of a genome-wide association study (GWAS) of ovarian cancer including 22,406 EOC cases and 40,941 controls to investigate genetically predicted DNA methylation levels in association with EOC risk. Among 62,938 CpG sites investigated, genetically predicted methylation levels at 89 CpG were significantly associated with EOC risk at a Bonferroni-corrected threshold of P < 7.94 × 10-7. Of them, 87 were located at GWAS-identified EOC susceptibility regions and two resided in a genomic region not previously reported to be associated with EOC risk. Integrative analyses of genetic, methylation, and gene expression data identified consistent directions of associations across 12 CpG, five genes, and EOC risk, suggesting that methylation at these 12 CpG may influence EOC risk by regulating expression of these five genes, namely MAPT, HOXB3, ABHD8, ARHGAP27, and SKAP1. We identified novel DNA methylation markers associated with EOC risk and propose that methylation at multiple CpG may affect EOC risk via regulation of gene expression. SIGNIFICANCE: Identification of novel DNA methylation markers associated with EOC risk suggests that methylation at multiple CpG may affect EOC risk through regulation of gene expression.
Published: 2019

18. Shared heritability and functional enrichment across six solid cancers.

Author: Jiang, Xia, Finucane, Hilary K, Schumacher, Fredrick R, Schmit, Stephanie L, Tyrer, Jonathan P, Han, Younghun, Michailidou, Kyriaki, Lesseur, Corina, Kuchenbaecker, Karoline B, Dennis, Joe, Conti, David V, Casey, Graham, Gaudet, Mia M, Huyghe, Jeroen R, Albanes, Demetrius, Aldrich, Melinda C, Andrew, Angeline S, Andrulis, Irene L, Anton-Culver, Hoda, Antoniou, Antonis C, Antonenkova, Natalia N, Arnold, Susanne M, Aronson, Kristan J, Arun, Banu K, Bandera, Elisa V, Barkardottir, Rosa B, Barnes, Daniel R, Batra, Jyotsna, Beckmann, Matthias W, Benitez, Javier, Benlloch, Sara, Berchuck, Andrew, Berndt, Sonja I, Bickeböller, Heike, Bien, Stephanie A, Blomqvist, Carl, Boccia, Stefania, Bogdanova, Natalia V, Bojesen, Stig E, Bolla, Manjeet K, Brauch, Hiltrud, Brenner, Hermann, Brenton, James D, Brook, Mark N, Brunet, Joan, Brunnström, Hans, Buchanan, Daniel D, Burwinkel, Barbara, Butzow, Ralf, Cadoni, Gabriella, Caldés, Trinidad, Caligo, Maria A, Campbell, Ian, Campbell, Peter T, Cancel-Tassin, Géraldine, Cannon-Albright, Lisa, Campa, Daniele, Caporaso, Neil, Carvalho, André L, Chan, Andrew T, Chang-Claude, Jenny, Chanock, Stephen J, Chen, Chu, Christiani, David C, Claes, Kathleen BM, Claessens, Frank, Clements, Judith, Collée, J Margriet, Correa, Marcia Cruz, Couch, Fergus J, Cox, Angela, Cunningham, Julie M, Cybulski, Cezary, Czene, Kamila, Daly, Mary B, deFazio, Anna, Devilee, Peter, Diez, Orland, Gago-Dominguez, Manuela, Donovan, Jenny L, Dörk, Thilo, Duell, Eric J, Dunning, Alison M, Dwek, Miriam, Eccles, Diana M, Edlund, Christopher K, Edwards, Digna R Velez, Ellberg, Carolina, Evans, D Gareth, Fasching, Peter A, Ferris, Robert L, Liloglou, Triantafillos, Figueiredo, Jane C, Fletcher, Olivia, Fortner, Renée T, Fostira, Florentia, Franceschi, Silvia, Friedman, Eitan, Gallinger, Steven J, and Ganz, Patricia A
Subjects: Humans, Breast Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Genetic Predisposition to Disease, Neoplasm Proteins, Case-Control Studies, Smoking, Mental Disorders, Inheritance Patterns, Phenotype, Polymorphism, Single Nucleotide, European Continental Ancestry Group, Female, Male, Genome-Wide Association Study, Polymorphism, Single Nucleotide, Prevention, Cancer, Breast Cancer, Genetics, Rare Diseases, Lung Cancer, Human Genome, Colo-Rectal Cancer, Digestive Diseases, Lung, MD Multidisciplinary
Abstract: Quantifying the genetic correlation between cancers can provide important insights into the mechanisms driving cancer etiology. Using genome-wide association study summary statistics across six cancer types based on a total of 296,215 cases and 301,319 controls of European ancestry, here we estimate the pair-wise genetic correlations between breast, colorectal, head/neck, lung, ovary and prostate cancer, and between cancers and 38 other diseases. We observed statistically significant genetic correlations between lung and head/neck cancer (rg = 0.57, p = 4.6 × 10-8), breast and ovarian cancer (rg = 0.24, p = 7 × 10-5), breast and lung cancer (rg = 0.18, p =1.5 × 10-6) and breast and colorectal cancer (rg = 0.15, p = 1.1 × 10-4). We also found that multiple cancers are genetically correlated with non-cancer traits including smoking, psychiatric diseases and metabolic characteristics. Functional enrichment analysis revealed a significant excess contribution of conserved and regulatory regions to cancer heritability. Our comprehensive analysis of cross-cancer heritability suggests that solid tumors arising across tissues share in part a common germline genetic basis.
Published: 2019

19. Circulating inflammatory biomarkers, adipokines and breast cancer risk—a case-control study nested within the EPIC cohort

Author: Cairat, Manon, Rinaldi, Sabina, Navionis, Anne-Sophie, Romieu, Isabelle, Biessy, Carine, Viallon, Vivian, Olsen, Anja, Tjønneland, Anne, Fournier, Agnès, Severi, Gianluca, Kvaskoff, Marina, Fortner, Renée T., Kaaks, Rudolf, Aleksandrova, Krasimira, Schulze, Matthias B., Masala, Giovanna, Tumino, Rosario, Sieri, Sabina, Grasso, Chiara, Mattiello, Amalia, Gram, Inger T., Olsen, Karina Standahl, Agudo, Antonio, Etxezarreta, Pilar Amiano, Sánchez, Maria-Jose, Santiuste, Carmen, Barricarte, Aurelio, Monninkhof, Evelyn, Hiensch, Anouk E., Muller, David, Merritt, Melissa A., Travis, Ruth C., Weiderpass, Elisabete, Gunter, Marc J., and Dossus, Laure
Published: 2022
Full Text: View/download PDF

20. Validation of miRNA signatures for ovarian cancer earlier detection in the pre-diagnosis setting using machine learning approaches.

Author: Stawiski, Konrad, Fortner, Renée T., Pestarino, Luca, Umu, Sinan U., Kaaks, Rudolf, Rounge, Trine B., Elias, Kevin M., Fendler, Wojciech, and Langseth, Hilde
Subjects: OVARIAN cancer, MACHINE learning, EARLY detection of cancer, RECEIVER operating characteristic curves, MICRORNA, OVARIAN epithelial cancer
Abstract: Introduction: Effective strategies for early detection of epithelial ovarian cancer are lacking. We evaluated whether a panel of 14 previously established circulating microRNAs could discriminate between cases diagnosed <2 years after serum collection and those diagnosed 2-7 years after serum collection. miRNA sequencing data from subsequent ovarian cancer cases were obtained as part of the ongoing multi-cancer JanusRNA project, utilizing pre-diagnostic serum samples from the Janus Serum Bank and linked to the Cancer Registry of Norway for cancer outcomes. Methods: We included a total of 80 ovarian cancer cases contributing 80 serum samples and compared 40 serum samples from cases with samples collected <2 years prior to diagnosis with 40 serum samples from cases with sample collection =2 to 7 years. We employed the extreme gradient boosting (XGBoost) algorithm to train a binary classification model using 70% of the available data, while the model was tested on the remaining 30% of the dataset. Results: The performance of the model was evaluated using repeated holdout validation. The previously established set of miRNAs achieved a median area under the receiver operating characteristic curve (AUC) of 0.771 in the test sets. Four out of 14 miRNAs (hsa-miR-200a-3p, hsa-miR-1246, hsa-miR-203a-3p, hsa-miR-23b-3p) exhibited higher expression levels closer to diagnosis, consistent with the previously reported upregulation in cancer cases, with statistical significance observed only for hsa-miR-200a-3p (beta=0.14; p=0.04). Discussion: The discrimination potential of the selected models provides evidence of the robustness of the miRNA signature for ovarian cancer. [ABSTRACT FROM AUTHOR]
Published: 2024
Full Text: View/download PDF

21. A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk

Author: Lu, Yingchang, Beeghly-Fadiel, Alicia, Wu, Lang, Guo, Xingyi, Li, Bingshan, Schildkraut, Joellen M, Im, Hae Kyung, Chen, Yian A, Permuth, Jennifer B, Reid, Brett M, Teer, Jamie K, Moysich, Kirsten B, Andrulis, Irene L, Anton-Culver, Hoda, Arun, Banu K, Bandera, Elisa V, Barkardottir, Rosa B, Barnes, Daniel R, Benitez, Javier, Bjorge, Line, Brenton, James, Butzow, Ralf, Caldes, Trinidad, Caligo, Maria A, Campbell, Ian, Chang-Claude, Jenny, Claes, Kathleen BM, Couch, Fergus J, Cramer, Daniel W, Daly, Mary B, deFazio, Anna, Dennis, Joe, Diez, Orland, Domchek, Susan M, Dörk, Thilo, Easton, Douglas F, Eccles, Diana M, Fasching, Peter A, Fortner, Renée T, Fountzilas, George, Friedman, Eitan, Ganz, Patricia A, Garber, Judy, Giles, Graham G, Godwin, Andrew K, Goldgar, David E, Goodman, Marc T, Greene, Mark H, Gronwald, Jacek, Hamann, Ute, Heitz, Florian, Hildebrandt, Michelle AT, Høgdall, Claus K, Hollestelle, Antoinette, Hulick, Peter J, Huntsman, David G, Imyanitov, Evgeny N, Isaacs, Claudine, Jakubowska, Anna, James, Paul, Karlan, Beth Y, Kelemen, Linda E, Kiemeney, Lambertus A, Kjaer, Susanne K, Kwong, Ava, Le, Nhu D, Leslie, Goska, Lesueur, Fabienne, Levine, Douglas A, Mattiello, Amalia, May, Taymaa, McGuffog, Lesley, McNeish, Iain A, Merritt, Melissa A, Modugno, Francesmary, Montagna, Marco, Neuhausen, Susan L, Nevanlinna, Heli, Nielsen, Finn C, Nikitina-Zake, Liene, Nussbaum, Robert L, Offit, Kenneth, Olah, Edith, Olopade, Olufunmilayo I, Olson, Sara H, Olsson, Håkan, Osorio, Ana, Park, Sue K, Parsons, Michael T, Peeters, Petra HM, Pejovic, Tanja, Peterlongo, Paolo, Phelan, Catherine M, Pujana, Miquel Angel, Ramus, Susan J, Rennert, Gad, Risch, Harvey, Rodriguez, Gustavo C, Rodríguez-Antona, Cristina, and Romieu, Isabelle
Subjects: Biological Sciences, Biomedical and Clinical Sciences, Genetics, Prevention, Human Genome, Ovarian Cancer, Rare Diseases, Cancer, 2.1 Biological and endogenous factors, Aetiology, Carcinogenesis, Carcinoma, Ovarian Epithelial, Cohort Studies, Female, Gene Expression Profiling, Genetic Predisposition to Disease, Genome-Wide Association Study, Genotype, Humans, Ovarian Neoplasms, Polymorphism, Single Nucleotide, Prognosis, Quantitative Trait Loci, Risk Factors, Transcriptome, Oncology and Carcinogenesis, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract: Large-scale genome-wide association studies (GWAS) have identified approximately 35 loci associated with epithelial ovarian cancer (EOC) risk. The majority of GWAS-identified disease susceptibility variants are located in noncoding regions, and causal genes underlying these associations remain largely unknown. Here, we performed a transcriptome-wide association study to search for novel genetic loci and plausible causal genes at known GWAS loci. We used RNA sequencing data (68 normal ovarian tissue samples from 68 individuals and 6,124 cross-tissue samples from 369 individuals) and high-density genotyping data from European descendants of the Genotype-Tissue Expression (GTEx V6) project to build ovarian and cross-tissue models of genetically regulated expression using elastic net methods. We evaluated 17,121 genes for their cis-predicted gene expression in relation to EOC risk using summary statistics data from GWAS of 97,898 women, including 29,396 EOC cases. With a Bonferroni-corrected significance level of P < 2.2 × 10-6, we identified 35 genes, including FZD4 at 11q14.2 (Z = 5.08, P = 3.83 × 10-7, the cross-tissue model; 1 Mb away from any GWAS-identified EOC risk variant), a potential novel locus for EOC risk. All other 34 significantly associated genes were located within 1 Mb of known GWAS-identified loci, including 23 genes at 6 loci not previously linked to EOC risk. Upon conditioning on nearby known EOC GWAS-identified variants, the associations for 31 genes disappeared and three genes remained (P < 1.47 × 10-3). These data identify one novel locus (FZD4) and 34 genes at 13 known EOC risk loci associated with EOC risk, providing new insights into EOC carcinogenesis.Significance: Transcriptomic analysis of a large cohort confirms earlier GWAS loci and reveals FZD4 as a novel locus associated with EOC risk. Cancer Res; 78(18); 5419-30. ©2018 AACR.
Published: 2018

22. Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study

Author: Ong, Jue-Sheng, Hwang, Liang-Dar, Cuellar-Partida, Gabriel, Martin, Nicholas G, Chenevix-Trench, Georgia, Quinn, Michael CJ, Cornelis, Marilyn C, Gharahkhani, Puya, Webb, Penelope M, MacGregor, Stuart, Bryne, Enda, Fasching, Peter A, Hein, Alexander, Burghaus, Stefanie, Beckmann, Matthias W, Lambrechts, Diether, Van Nieuwenhuysen, Els, Vergote, Ignace, Vanderstichele, Adriaan, Swerdlow, Anthony J, Jones, Michael, Orr, Nicholas, Schoemaker, Minouk, Edwards, Digna Velez, Brenton, James, Benítez, Javier, García, María J, Rodriguez-Antona, Cristina, Rossing, Mary Anne, Fortner, Renée T, Riboli, Elio, Chang-Claude, Jenny, Eilber, Ursula, Wang-Gohrke, Shan, Yannoukakos, Drakoulis, Goodman, Marc T, Bogdanova, Natalia, Dörk, Thilo, Duerst, Matthias, Hillemanns, Peter, Runnebaum, Ingo B, Antonenkova, Natalia, Butzow, Ralf, Nevanlinna, Heli, Pelttari, Liisa M, Edwards, Robert P, Kelley, Joseph L, Modugno, Francesmary, Moysich, Kirsten B, Ness, Roberta B, Cannioto, Rikki, Heitz, Florian, Karlan, Beth, Olsson, Håkan, Kjaer, Susanne K, Jensen, Allan, Giles, Graham G, Bruinsma, Fiona, Hildebrandt, Michelle AT, Liang, Dong, Wu, Xifeng, Le Marchand, Loic, Setiawan, V Wendy, Permuth, Jennifer B, Bisogna, Maria, Dao, Fanny, Levine, Douglas A, Cramer, Daniel W, Terry, Kathryn L, Tworoger, Shelley S, Stampfer, Meir, Willet, Walter, Missmer, Stacey, Bjorge, Line, Kopperud, Reidun K, Bischof, Katharina, Thomsen, Liv Cecilie Vestrheim, Kiemeney, Lambertus A, Massuger, Leon FAG, Pejovic, Tanja, Brooks-Wilson, Angela, Olson, Sara H, McGuire, Valerie, Rothstein, Joseph H, Sieh, Weiva, Whittemore, Alice S, Cook, Linda S, Le, Nhu D, Gilks, C Blake, Gronwald, Jacek, Jakubowska, Anna, Lubiński, Jan, Kluz, Tomasz, Wentzensen, Nicolas, Brinton, Louise, Trabert, Britton, and Lissowska, Jolanta
Subjects: Epidemiology, Health Sciences, Clinical Research, Ovarian Cancer, Nutrition, Rare Diseases, Prevention, Cancer, Genetics, 2.1 Biological and endogenous factors, Aetiology, Carcinoma, Ovarian Epithelial, Coffee, Female, Humans, Mendelian Randomization Analysis, Odds Ratio, Ovarian Neoplasms, Polymorphism, Single Nucleotide, Risk Factors, Ovarian Cancer Association Consortium, Statistics, Public Health and Health Services, Public health
Abstract: BackgroundCoffee consumption has been shown to be associated with various health outcomes in observational studies. However, evidence for its association with epithelial ovarian cancer (EOC) is inconsistent and it is unclear whether these associations are causal.MethodsWe used single nucleotide polymorphisms associated with (i) coffee and (ii) caffeine consumption to perform Mendelian randomization (MR) on EOC risk. We conducted a two-sample MR using genetic data on 44 062 individuals of European ancestry from the Ovarian Cancer Association Consortium (OCAC), and combined instrumental variable estimates using a Wald-type ratio estimator.ResultsFor all EOC cases, the causal odds ratio (COR) for genetically predicted consumption of one additional cup of coffee per day was 0.92 [95% confidence interval (CI): 0.79, 1.06]. The COR was 0.90 (95% CI: 0.73, 1.10) for high-grade serous EOC. The COR for genetically predicted consumption of an additional 80 mg caffeine was 1.01 (95% CI: 0.92, 1.11) for all EOC cases and 0.90 (95% CI: 0.73, 1.10) for high-grade serous cases.ConclusionsWe found no evidence indicative of a strong association between EOC risk and genetically predicted coffee or caffeine levels. However, our estimates were not statistically inconsistent with earlier observational studies and we were unable to rule out small protective associations.
Published: 2018

23. Offspring sex and risk of epithelial ovarian cancer : a multinational pooled analysis of 12 case–control studies

Author: AOCS Group, Modugno, Francesmary, Fu, Zhuxuan, Jordan, Susan J., Chang-Claude, Jenny, Fortner, Renée T., Goodman, Marc T., Moysich, Kirsten B., Schildkraut, Joellen M., Berchuck, Andrew, Bandera, Elisa V., Qin, Bo, Sutphen, Rebecca, McLaughlin, John R., Menon, Usha, Ramus, Susan J., Gayther, Simon A., Gentry-Maharaj, Aleksandra, Karpinskyj, Chloe, Pearce, Celeste L., Wu, Anna H., Risch, Harvey A., and Webb, Penelope M.
Published: 2020

24. Oral contraceptive use by formulation and endometrial cancer risk among women born in 1947–1964: The Nurses’ Health Study II, a prospective cohort study

Author: Burchardt, Norah A., Shafrir, Amy L., Kaaks, Rudolf, Tworoger, Shelley S., and Fortner, Renée T.
Published: 2021
Full Text: View/download PDF

25. Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case–control studies

Author: Modugno, Francesmary, Fu, Zhuxuan, Jordan, Susan J., Group, AOCS, Chang-Claude, Jenny, Fortner, Renée T., Goodman, Marc T., Moysich, Kirsten B., Schildkraut, Joellen M., Berchuck, Andrew, Bandera, Elisa V., Qin, Bo, Sutphen, Rebecca, McLaughlin, John R., Menon, Usha, Ramus, Susan J., Gayther, Simon A., Gentry-Maharaj, Aleksandra, Karpinskyj, Chloe, Pearce, Celeste L., Wu, Anna H., Risch, Harvey A., and Webb, Penelope M.
Published: 2020
Full Text: View/download PDF

26. Metabolic signatures of greater body size and their associations with risk of colorectal and endometrial cancers in the European Prospective Investigation into Cancer and Nutrition

Author: Kliemann, Nathalie, Viallon, Vivian, Murphy, Neil, Beeken, Rebecca J., Rothwell, Joseph A., Rinaldi, Sabina, Assi, Nada, van Roekel, Eline H., Schmidt, Julie A., Borch, Kristin Benjaminsen, Agnoli, Claudia, Rosendahl, Ann H., Sartor, Hanna, Huerta, José María, Tjønneland, Anne, Halkjær, Jytte, Bueno-de-Mesquita, Bas, Gicquiau, Audrey, Achaintre, David, Aleksandrova, Krasimira, Schulze, Matthias B., Heath, Alicia K., Tsilidis, Konstantinos K., Masala, Giovanna, Panico, Salvatore, Kaaks, Rudolf, Fortner, Renée T., Van Guelpen, Bethany, Dossus, Laure, Scalbert, Augustin, Keun, Hector C., Travis, Ruth C., Jenab, Mazda, Johansson, Mattias, Ferrari, Pietro, and Gunter, Marc J.
Published: 2021
Full Text: View/download PDF

27. Dietary intake of trans fatty acids and breast cancer risk in 9 European countries

Author: Matta, Michèle, Huybrechts, Inge, Biessy, Carine, Casagrande, Corinne, Yammine, Sahar, Fournier, Agnès, Olsen, Karina Standahl, Lukic, Marco, Gram, Inger Torhild, Ardanaz, Eva, Sánchez, Maria-José, Dossus, Laure, Fortner, Renée T., Srour, Bernard, Jannasch, Franziska, Schulze, Matthias B., Amiano, Pilar, Agudo, Antonio, Colorado-Yohar, Sandra, Quirós, J. Ramón, Tumino, Rosario, Panico, Salvatore, Masala, Giovanna, Pala, Valeria, Sacerdote, Carlotta, Tjønneland, Anne, Olsen, Anja, Dahm, Christina C., Rosendahl, Ann H., Borgquist, Signe, Wennberg, Maria, Heath, Alicia K., Aune, Dagfinn, Schmidt, Julie, Weiderpass, Elisabete, Chajes, Veronique, Gunter, Marc J., and Murphy, Neil
Published: 2021
Full Text: View/download PDF

28. Coffee and tea drinking in relation to the risk of differentiated thyroid carcinoma: results from the European Prospective Investigation into Cancer and Nutrition (EPIC) study

Author: Zamora-Ros, Raul, Alghamdi, Muath A., Cayssials, Valerie, Franceschi, Silvia, Almquist, Martin, Hennings, Joakim, Sandström, Maria, Tsilidis, Konstantinos K., Weiderpass, Elisabete, Boutron-Ruault, Marie-Christine, Hammer Bech, Bodil, Overvad, Kim, Tjønneland, Anne, Petersen, Kristina E. N., Mancini, Francesca Romana, Mahamat-Saleh, Yahya, Bonnet, Fabrice, Kühn, Tilman, Fortner, Renée T., Boeing, Heiner, Trichopoulou, Antonia, Bamia, Christina, Martimianaki, Georgia, Masala, Giovanna, Grioni, Sara, Panico, Salvatore, Tumino, Rosario, Fasanelli, Francesca, Skeie, Guri, Braaten, Tonje, Lasheras, Cristina, Salamanca-Fernández, Elena, Amiano, Pilar, Chirlaque, Maria-Dolores, Barricarte, Aurelio, Manjer, Jonas, Wallström, Peter, Bueno-de-Mesquita, H. Bas, Peeters, Petra H., Khaw, Kay-Thee, Wareham, Nicholas J., Schmidt, Julie A., Aune, Dagfinn, Byrnes, Graham, Scalbert, Augustin, Agudo, Antonio, and Rinaldi, Sabina
Published: 2019
Full Text: View/download PDF

29. Reproducibility of serum oxysterols and lanosterol among postmenopausal women: Results from EPIC-Heidelberg

Author: Lu, Da-Lin, Sookthai, Disorn, Le Cornet, Charlotte, Katzke, Verena A., Johnson, Theron S., Kaaks, Rudolf, and Fortner, Renée T.
Published: 2018
Full Text: View/download PDF

30. Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes : A collaborative re-analysis from the Ovarian Cancer Cohort Consortium

Author: Ose, Jennifer, Schock, Helena, Poole, Elizabeth M., Lehtinen, Matti, Visvanathan, Kala, Helzlsouer, Kathy, Buring, Julie E., Lee, I-Min, Tjønneland, Anne, Boutron-Ruault, Marie-Christine, Trichopoulou, Antonia, Mattiello, Amalia, Onland-Moret, N. Charlotte, Weiderpass, Elisabete, Sánchez, María-José, Idahl, Annika, Travis, Ruth C., Rinaldi, Sabina, Merritt, Melissa A., Wentzensen, Nicolas, Tworoger, Shelley S., Kaaks, Rudolf, and Fortner, Renée T.
Published: 2017

31. Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Finnish Maternity Cohort

Author: Skarga, Elizaveta, primary, Surcel, Heljä-Marja, additional, Kaaks, Rudolf, additional, Waterboer, Tim, additional, and Fortner, Renée T, additional
Published: 2023
Full Text: View/download PDF

32. Data from Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort

Author: Sarink, Danja, primary, Schock, Helena, primary, Johnson, Theron, primary, Overvad, Kim, primary, Holm, Marianne, primary, Tjønneland, Anne, primary, Boutron-Ruault, Marie-Christine, primary, His, Mathilde, primary, Kvaskoff, Marina, primary, Boeing, Heiner, primary, Lagiou, Pagona, primary, Papatesta, Eleni-Maria, primary, Trichopoulou, Antonia, primary, Palli, Domenico, primary, Pala, Valeria, primary, Mattiello, Amalia, primary, Tumino, Rosario, primary, Sacerdote, Carlotta, primary, Bueno-de-Mesquita, H.B(as)., primary, van Gils, Carla H., primary, Peeters, Petra H., primary, Weiderpass, Elisabete, primary, Agudo, Antonio, primary, Sánchez, Maria-José, primary, Chirlaque, Maria-Dolores, primary, Ardanaz, Eva, primary, Amiano, Pilar, primary, Khaw, Kay Tee, primary, Travis, Ruth, primary, Dossus, Laure, primary, Gunter, Mark, primary, Rinaldi, Sabina, primary, Merritt, Melissa, primary, Riboli, Elio, primary, Kaaks, Rudolf, primary, and Fortner, Renée T., primary
Published: 2023
Full Text: View/download PDF

33. Supplementary Tables 1-6 from Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort

Author: Sarink, Danja, primary, Schock, Helena, primary, Johnson, Theron, primary, Overvad, Kim, primary, Holm, Marianne, primary, Tjønneland, Anne, primary, Boutron-Ruault, Marie-Christine, primary, His, Mathilde, primary, Kvaskoff, Marina, primary, Boeing, Heiner, primary, Lagiou, Pagona, primary, Papatesta, Eleni-Maria, primary, Trichopoulou, Antonia, primary, Palli, Domenico, primary, Pala, Valeria, primary, Mattiello, Amalia, primary, Tumino, Rosario, primary, Sacerdote, Carlotta, primary, Bueno-de-Mesquita, H.B(as)., primary, van Gils, Carla H., primary, Peeters, Petra H., primary, Weiderpass, Elisabete, primary, Agudo, Antonio, primary, Sánchez, Maria-José, primary, Chirlaque, Maria-Dolores, primary, Ardanaz, Eva, primary, Amiano, Pilar, primary, Khaw, Kay Tee, primary, Travis, Ruth, primary, Dossus, Laure, primary, Gunter, Mark, primary, Rinaldi, Sabina, primary, Merritt, Melissa, primary, Riboli, Elio, primary, Kaaks, Rudolf, primary, and Fortner, Renée T., primary
Published: 2023
Full Text: View/download PDF

34. Obesity and Breast Cancer

Author: Fortner, Renée T., Katzke, Verena, Kühn, Tilman, Kaaks, Rudolf, Schlag, Peter M., Series editor, Senn, Hans-Jörg, Series editor, Pischon, Tobias, editor, and Nimptsch, Katharina, editor
Published: 2016
Full Text: View/download PDF

35. Circulating 27-hydroxycholesterol and breast cancer tissue expression of CYP27A1, CYP7B1, LXR-β, and ERβ: results from the EPIC-Heidelberg cohort

Author: Le Cornet, Charlotte, Walter, Britta, Sookthai, Disorn, Johnson, Theron S., Kühn, Tilman, Herpel, Ester, Kaaks, Rudolf, and Fortner, Renée T.
Published: 2020
Full Text: View/download PDF

36. Development and validation of circulating CA125 prediction models in postmenopausal women

Author: Sasamoto, Naoko, Babic, Ana, Rosner, Bernard A., Fortner, Renée T., Vitonis, Allison F., Yamamoto, Hidemi, Fichorova, Raina N., Titus, Linda J., Tjønneland, Anne, Hansen, Louise, Kvaskoff, Marina, Fournier, Agnès, Mancini, Francesca Romana, Boeing, Heiner, Trichopoulou, Antonia, Peppa, Eleni, Karakatsani, Anna, Palli, Domenico, Grioni, Sara, Mattiello, Amalia, Tumino, Rosario, Fiano, Valentina, Onland-Moret, N. Charlotte, Weiderpass, Elisabete, Gram, Inger T., Quirós, J. Ramón, Lujan-Barroso, Leila, Sánchez, Maria-Jose, Colorado-Yohar, Sandra, Barricarte, Aurelio, Amiano, Pilar, Idahl, Annika, Lundin, Eva, Sartor, Hanna, Khaw, Kay-Tee, Key, Timothy J., Muller, David, Riboli, Elio, Gunter, Marc, Dossus, Laure, Trabert, Britton, Wentzensen, Nicolas, Kaaks, Rudolf, Cramer, Daniel W., Tworoger, Shelley S., and Terry, Kathryn L.
Published: 2019
Full Text: View/download PDF

37. Table S1 from A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk

Author: Lu, Yingchang, primary, Beeghly-Fadiel, Alicia, primary, Wu, Lang, primary, Guo, Xingyi, primary, Li, Bingshan, primary, Schildkraut, Joellen M., primary, Im, Hae Kyung, primary, Chen, Yian A., primary, Permuth, Jennifer B., primary, Reid, Brett M., primary, Teer, Jamie K., primary, Moysich, Kirsten B., primary, Andrulis, Irene L., primary, Anton-Culver, Hoda, primary, Arun, Banu K., primary, Bandera, Elisa V., primary, Barkardottir, Rosa B., primary, Barnes, Daniel R., primary, Benitez, Javier, primary, Bjorge, Line, primary, Brenton, James, primary, Butzow, Ralf, primary, Caldes, Trinidad, primary, Caligo, Maria A., primary, Campbell, Ian, primary, Chang-Claude, Jenny, primary, Claes, Kathleen B.M., primary, Couch, Fergus J., primary, Cramer, Daniel W., primary, Daly, Mary B., primary, deFazio, Anna, primary, Dennis, Joe, primary, Diez, Orland, primary, Domchek, Susan M., primary, Dörk, Thilo, primary, Easton, Douglas F., primary, Eccles, Diana M., primary, Fasching, Peter A., primary, Fortner, Renée T., primary, Fountzilas, George, primary, Friedman, Eitan, primary, Ganz, Patricia A., primary, Garber, Judy, primary, Giles, Graham G., primary, Godwin, Andrew K., primary, Goldgar, David E., primary, Goodman, Marc T., primary, Greene, Mark H., primary, Gronwald, Jacek, primary, Hamann, Ute, primary, Heitz, Florian, primary, Hildebrandt, Michelle A.T., primary, Høgdall, Claus K., primary, Hollestelle, Antoinette, primary, Hulick, Peter J., primary, Huntsman, David G., primary, Imyanitov, Evgeny N., primary, Isaacs, Claudine, primary, Jakubowska, Anna, primary, James, Paul, primary, Karlan, Beth Y., primary, Kelemen, Linda E., primary, Kiemeney, Lambertus A., primary, Kjaer, Susanne K., primary, Kwong, Ava, primary, Le, Nhu D., primary, Leslie, Goska, primary, Lesueur, Fabienne, primary, Levine, Douglas A., primary, Mattiello, Amalia, primary, May, Taymaa, primary, McGuffog, Lesley, primary, McNeish, Iain A., primary, Merritt, Melissa A., primary, Modugno, Francesmary, primary, Montagna, Marco, primary, Neuhausen, Susan L., primary, Nevanlinna, Heli, primary, Nielsen, Finn C., primary, Nikitina-Zake, Liene, primary, Nussbaum, Robert L., primary, Offit, Kenneth, primary, Olah, Edith, primary, Olopade, Olufunmilayo I., primary, Olson, Sara H., primary, Olsson, Håkan, primary, Osorio, Ana, primary, Park, Sue K., primary, Parsons, Michael T., primary, Peeters, Petra H.M., primary, Pejovic, Tanja, primary, Peterlongo, Paolo, primary, Phelan, Catherine M., primary, Pujana, Miquel Angel, primary, Ramus, Susan J., primary, Rennert, Gad, primary, Risch, Harvey, primary, Rodriguez, Gustavo C., primary, Rodríguez-Antona, Cristina, primary, Romieu, Isabelle, primary, Rookus, Matti A., primary, Rossing, Mary Anne, primary, Rzepecka, Iwona K., primary, Sandler, Dale P., primary, Schmutzler, Rita K., primary, Setiawan, Veronica W., primary, Sharma, Priyanka, primary, Sieh, Weiva, primary, Simard, Jacques, primary, Singer, Christian F., primary, Song, Honglin, primary, Southey, Melissa C., primary, Spurdle, Amanda B., primary, Sutphen, Rebecca, primary, Swerdlow, Anthony J., primary, Teixeira, Manuel R., primary, Teo, Soo H., primary, Thomassen, Mads, primary, Tischkowitz, Marc, primary, Toland, Amanda E., primary, Trichopoulou, Antonia, primary, Tung, Nadine, primary, Tworoger, Shelley S., primary, van Rensburg, Elizabeth J., primary, Vanderstichele, Adriaan, primary, Vega, Ana, primary, Edwards, Digna Velez, primary, Webb, Penelope M., primary, Weitzel, Jeffrey N., primary, Wentzensen, Nicolas, primary, White, Emily, primary, Wolk, Alicja, primary, Wu, Anna H., primary, Yannoukakos, Drakoulis, primary, Zorn, Kristin K., primary, Gayther, Simon A., primary, Antoniou, Antonis C., primary, Berchuck, Andrew, primary, Goode, Ellen L., primary, Chenevix-Trench, Georgia, primary, Sellers, Thomas A., primary, Pharoah, Paul D.P., primary, Zheng, Wei, primary, and Long, Jirong, primary
Published: 2023
Full Text: View/download PDF

38. Online Supplementary Materials from A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk

Author: Lu, Yingchang, primary, Beeghly-Fadiel, Alicia, primary, Wu, Lang, primary, Guo, Xingyi, primary, Li, Bingshan, primary, Schildkraut, Joellen M., primary, Im, Hae Kyung, primary, Chen, Yian A., primary, Permuth, Jennifer B., primary, Reid, Brett M., primary, Teer, Jamie K., primary, Moysich, Kirsten B., primary, Andrulis, Irene L., primary, Anton-Culver, Hoda, primary, Arun, Banu K., primary, Bandera, Elisa V., primary, Barkardottir, Rosa B., primary, Barnes, Daniel R., primary, Benitez, Javier, primary, Bjorge, Line, primary, Brenton, James, primary, Butzow, Ralf, primary, Caldes, Trinidad, primary, Caligo, Maria A., primary, Campbell, Ian, primary, Chang-Claude, Jenny, primary, Claes, Kathleen B.M., primary, Couch, Fergus J., primary, Cramer, Daniel W., primary, Daly, Mary B., primary, deFazio, Anna, primary, Dennis, Joe, primary, Diez, Orland, primary, Domchek, Susan M., primary, Dörk, Thilo, primary, Easton, Douglas F., primary, Eccles, Diana M., primary, Fasching, Peter A., primary, Fortner, Renée T., primary, Fountzilas, George, primary, Friedman, Eitan, primary, Ganz, Patricia A., primary, Garber, Judy, primary, Giles, Graham G., primary, Godwin, Andrew K., primary, Goldgar, David E., primary, Goodman, Marc T., primary, Greene, Mark H., primary, Gronwald, Jacek, primary, Hamann, Ute, primary, Heitz, Florian, primary, Hildebrandt, Michelle A.T., primary, Høgdall, Claus K., primary, Hollestelle, Antoinette, primary, Hulick, Peter J., primary, Huntsman, David G., primary, Imyanitov, Evgeny N., primary, Isaacs, Claudine, primary, Jakubowska, Anna, primary, James, Paul, primary, Karlan, Beth Y., primary, Kelemen, Linda E., primary, Kiemeney, Lambertus A., primary, Kjaer, Susanne K., primary, Kwong, Ava, primary, Le, Nhu D., primary, Leslie, Goska, primary, Lesueur, Fabienne, primary, Levine, Douglas A., primary, Mattiello, Amalia, primary, May, Taymaa, primary, McGuffog, Lesley, primary, McNeish, Iain A., primary, Merritt, Melissa A., primary, Modugno, Francesmary, primary, Montagna, Marco, primary, Neuhausen, Susan L., primary, Nevanlinna, Heli, primary, Nielsen, Finn C., primary, Nikitina-Zake, Liene, primary, Nussbaum, Robert L., primary, Offit, Kenneth, primary, Olah, Edith, primary, Olopade, Olufunmilayo I., primary, Olson, Sara H., primary, Olsson, Håkan, primary, Osorio, Ana, primary, Park, Sue K., primary, Parsons, Michael T., primary, Peeters, Petra H.M., primary, Pejovic, Tanja, primary, Peterlongo, Paolo, primary, Phelan, Catherine M., primary, Pujana, Miquel Angel, primary, Ramus, Susan J., primary, Rennert, Gad, primary, Risch, Harvey, primary, Rodriguez, Gustavo C., primary, Rodríguez-Antona, Cristina, primary, Romieu, Isabelle, primary, Rookus, Matti A., primary, Rossing, Mary Anne, primary, Rzepecka, Iwona K., primary, Sandler, Dale P., primary, Schmutzler, Rita K., primary, Setiawan, Veronica W., primary, Sharma, Priyanka, primary, Sieh, Weiva, primary, Simard, Jacques, primary, Singer, Christian F., primary, Song, Honglin, primary, Southey, Melissa C., primary, Spurdle, Amanda B., primary, Sutphen, Rebecca, primary, Swerdlow, Anthony J., primary, Teixeira, Manuel R., primary, Teo, Soo H., primary, Thomassen, Mads, primary, Tischkowitz, Marc, primary, Toland, Amanda E., primary, Trichopoulou, Antonia, primary, Tung, Nadine, primary, Tworoger, Shelley S., primary, van Rensburg, Elizabeth J., primary, Vanderstichele, Adriaan, primary, Vega, Ana, primary, Edwards, Digna Velez, primary, Webb, Penelope M., primary, Weitzel, Jeffrey N., primary, Wentzensen, Nicolas, primary, White, Emily, primary, Wolk, Alicja, primary, Wu, Anna H., primary, Yannoukakos, Drakoulis, primary, Zorn, Kristin K., primary, Gayther, Simon A., primary, Antoniou, Antonis C., primary, Berchuck, Andrew, primary, Goode, Ellen L., primary, Chenevix-Trench, Georgia, primary, Sellers, Thomas A., primary, Pharoah, Paul D.P., primary, Zheng, Wei, primary, and Long, Jirong, primary
Published: 2023
Full Text: View/download PDF

39. Supplementary Table 1 from The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3)

Author: Trabert, Britton, primary, Tworoger, Shelley S., primary, O'Brien, Katie M., primary, Townsend, Mary K., primary, Fortner, Renée T., primary, Iversen, Edwin S., primary, Hartge, Patricia, primary, White, Emily, primary, Amiano, Pilar, primary, Arslan, Alan A., primary, Bernstein, Leslie, primary, Brinton, Louise A., primary, Buring, Julie E., primary, Dossus, Laure, primary, Fraser, Gary E., primary, Gaudet, Mia M., primary, Giles, Graham G., primary, Gram, Inger T., primary, Harris, Holly R., primary, Bolton, Judith Hoffman, primary, Idahl, Annika, primary, Jones, Michael E., primary, Kaaks, Rudolf, primary, Kirsh, Victoria A., primary, Knutsen, Synnove F., primary, Kvaskoff, Marina, primary, Lacey, James V., primary, Lee, I-Min, primary, Milne, Roger L., primary, Onland-Moret, N. Charlotte, primary, Overvad, Kim, primary, Patel, Alpa V., primary, Peters, Ulrike, primary, Poynter, Jenny N., primary, Riboli, Elio, primary, Robien, Kim, primary, Rohan, Thomas E., primary, Sandler, Dale P., primary, Schairer, Catherine, primary, Schouten, Leo J., primary, Setiawan, Veronica W., primary, Swerdlow, Anthony J., primary, Travis, Ruth C., primary, Trichopoulou, Antonia, primary, van den Brandt, Piet A., primary, Visvanathan, Kala, primary, Wilkens, Lynne R., primary, Wolk, Alicja, primary, Zeleniuch-Jacquotte, Anne, primary, and Wentzensen, Nicolas, primary
Published: 2023
Full Text: View/download PDF

40. Evaluation of added discriminatory ability from A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort

Author: Terry, Kathryn L., primary, Schock, Helena, primary, Fortner, Renée T., primary, Hüsing, Anika, primary, Fichorova, Raina N., primary, Yamamoto, Hidemi S., primary, Vitonis, Allison F., primary, Johnson, Theron, primary, Overvad, Kim, primary, Tjønneland, Anne, primary, Boutron-Ruault, Marie-Christine, primary, Mesrine, Sylvie, primary, Severi, Gianluca, primary, Dossus, Laure, primary, Rinaldi, Sabina, primary, Boeing, Heiner, primary, Benetou, Vassiliki, primary, Lagiou, Pagona, primary, Trichopoulou, Antonia, primary, Krogh, Vittorio, primary, Kuhn, Elisabetta, primary, Panico, Salvatore, primary, Bueno-de-Mesquita, H. Bas, primary, Onland-Moret, N. Charlotte, primary, Peeters, Petra H., primary, Gram, Inger Torhild, primary, Weiderpass, Elisabete, primary, Duell, Eric J., primary, Sanchez, Maria-Jose, primary, Ardanaz, Eva, primary, Etxezarreta, Nerea, primary, Navarro, Carmen, primary, Idahl, Annika, primary, Lundin, Eva, primary, Jirström, Karin, primary, Manjer, Jonas, primary, Wareham, Nicholas J., primary, Khaw, Kay-Tee, primary, Byrne, Karl Smith, primary, Travis, Ruth C., primary, Gunter, Marc J., primary, Merritt, Melissa A., primary, Riboli, Elio, primary, Cramer, Daniel W., primary, and Kaaks, Rudolf, primary
Published: 2023
Full Text: View/download PDF

41. Data from The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3)

Author: Trabert, Britton, primary, Tworoger, Shelley S., primary, O'Brien, Katie M., primary, Townsend, Mary K., primary, Fortner, Renée T., primary, Iversen, Edwin S., primary, Hartge, Patricia, primary, White, Emily, primary, Amiano, Pilar, primary, Arslan, Alan A., primary, Bernstein, Leslie, primary, Brinton, Louise A., primary, Buring, Julie E., primary, Dossus, Laure, primary, Fraser, Gary E., primary, Gaudet, Mia M., primary, Giles, Graham G., primary, Gram, Inger T., primary, Harris, Holly R., primary, Bolton, Judith Hoffman, primary, Idahl, Annika, primary, Jones, Michael E., primary, Kaaks, Rudolf, primary, Kirsh, Victoria A., primary, Knutsen, Synnove F., primary, Kvaskoff, Marina, primary, Lacey, James V., primary, Lee, I-Min, primary, Milne, Roger L., primary, Onland-Moret, N. Charlotte, primary, Overvad, Kim, primary, Patel, Alpa V., primary, Peters, Ulrike, primary, Poynter, Jenny N., primary, Riboli, Elio, primary, Robien, Kim, primary, Rohan, Thomas E., primary, Sandler, Dale P., primary, Schairer, Catherine, primary, Schouten, Leo J., primary, Setiawan, Veronica W., primary, Swerdlow, Anthony J., primary, Travis, Ruth C., primary, Trichopoulou, Antonia, primary, van den Brandt, Piet A., primary, Visvanathan, Kala, primary, Wilkens, Lynne R., primary, Wolk, Alicja, primary, Zeleniuch-Jacquotte, Anne, primary, and Wentzensen, Nicolas, primary
Published: 2023
Full Text: View/download PDF

42. Supplementary Table 2 from The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3)

Author: Trabert, Britton, primary, Tworoger, Shelley S., primary, O'Brien, Katie M., primary, Townsend, Mary K., primary, Fortner, Renée T., primary, Iversen, Edwin S., primary, Hartge, Patricia, primary, White, Emily, primary, Amiano, Pilar, primary, Arslan, Alan A., primary, Bernstein, Leslie, primary, Brinton, Louise A., primary, Buring, Julie E., primary, Dossus, Laure, primary, Fraser, Gary E., primary, Gaudet, Mia M., primary, Giles, Graham G., primary, Gram, Inger T., primary, Harris, Holly R., primary, Bolton, Judith Hoffman, primary, Idahl, Annika, primary, Jones, Michael E., primary, Kaaks, Rudolf, primary, Kirsh, Victoria A., primary, Knutsen, Synnove F., primary, Kvaskoff, Marina, primary, Lacey, James V., primary, Lee, I-Min, primary, Milne, Roger L., primary, Onland-Moret, N. Charlotte, primary, Overvad, Kim, primary, Patel, Alpa V., primary, Peters, Ulrike, primary, Poynter, Jenny N., primary, Riboli, Elio, primary, Robien, Kim, primary, Rohan, Thomas E., primary, Sandler, Dale P., primary, Schairer, Catherine, primary, Schouten, Leo J., primary, Setiawan, Veronica W., primary, Swerdlow, Anthony J., primary, Travis, Ruth C., primary, Trichopoulou, Antonia, primary, van den Brandt, Piet A., primary, Visvanathan, Kala, primary, Wilkens, Lynne R., primary, Wolk, Alicja, primary, Zeleniuch-Jacquotte, Anne, primary, and Wentzensen, Nicolas, primary
Published: 2023
Full Text: View/download PDF

43. Data from Human Chorionic Gonadotropin Does Not Correlate with Risk for Maternal Breast Cancer: Results from the Finnish Maternity Cohort

Author: Fortner, Renée T., primary, Schock, Helena, primary, Kaaks, Rudolf, primary, Lehtinen, Matti, primary, Pukkala, Eero, primary, Lakso, Hans-Åke, primary, Tanner, Minna, primary, Kallio, Raija, primary, Joensuu, Heikki, primary, Korpela, Jaana, primary, Toriola, Adetunji T., primary, Hallmans, Göran, primary, Grankvist, Kjell, primary, Zeleniuch-Jacquotte, Anne, primary, Toniolo, Paolo, primary, Lundin, Eva, primary, and Surcel, Heljä-Marja, primary
Published: 2023
Full Text: View/download PDF

44. Spearman coefficients of correlation from A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort

Author: Terry, Kathryn L., primary, Schock, Helena, primary, Fortner, Renée T., primary, Hüsing, Anika, primary, Fichorova, Raina N., primary, Yamamoto, Hidemi S., primary, Vitonis, Allison F., primary, Johnson, Theron, primary, Overvad, Kim, primary, Tjønneland, Anne, primary, Boutron-Ruault, Marie-Christine, primary, Mesrine, Sylvie, primary, Severi, Gianluca, primary, Dossus, Laure, primary, Rinaldi, Sabina, primary, Boeing, Heiner, primary, Benetou, Vassiliki, primary, Lagiou, Pagona, primary, Trichopoulou, Antonia, primary, Krogh, Vittorio, primary, Kuhn, Elisabetta, primary, Panico, Salvatore, primary, Bueno-de-Mesquita, H. Bas, primary, Onland-Moret, N. Charlotte, primary, Peeters, Petra H., primary, Gram, Inger Torhild, primary, Weiderpass, Elisabete, primary, Duell, Eric J., primary, Sanchez, Maria-Jose, primary, Ardanaz, Eva, primary, Etxezarreta, Nerea, primary, Navarro, Carmen, primary, Idahl, Annika, primary, Lundin, Eva, primary, Jirström, Karin, primary, Manjer, Jonas, primary, Wareham, Nicholas J., primary, Khaw, Kay-Tee, primary, Byrne, Karl Smith, primary, Travis, Ruth C., primary, Gunter, Marc J., primary, Merritt, Melissa A., primary, Riboli, Elio, primary, Cramer, Daniel W., primary, and Kaaks, Rudolf, primary
Published: 2023
Full Text: View/download PDF

45. Supplemental tables 1 and 2 from Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort

Author: Ose, Jennifer, primary, Schock, Helena, primary, Tjønneland, Anne, primary, Hansen, Louise, primary, Overvad, Kim, primary, Dossus, Laure, primary, Clavel-Chapelon, Françoise, primary, Baglietto, Laura, primary, Boeing, Heiner, primary, Trichopolou, Antonia, primary, Benetou, Vassiliki, primary, Lagiou, Pagona, primary, Masala, Giovanna, primary, Tagliabue, Giovanna, primary, Tumino, Rosario, primary, Sacerdote, Carlotta, primary, Mattiello, Amalia, primary, Bueno-de-Mesquita, H. B(as)., primary, Peeters, Petra H. M., primary, Onland-Moret, N. Charlotte, primary, Weiderpass, Elisabete, primary, Gram, Inger T., primary, Sánchez, Soledad, primary, Obon-Santacana, Mireia, primary, Sànchez-Pérez, Maria-José, primary, Larrañaga, Nerea, primary, Castaño, José María Huerta, primary, Ardanaz, Eva, primary, Brändstedt, Jenny, primary, Lundin, Eva, primary, Idahl, Annika, primary, Travis, Ruth C., primary, Khaw, Kay-Tee, primary, Rinaldi, Sabina, primary, Romieu, Isabelle, primary, Merritt, Melissa A., primary, Gunter, Marc J., primary, Riboli, Elio, primary, Kaaks, Rudolf, primary, and Fortner, Renée T., primary
Published: 2023
Full Text: View/download PDF

46. Supplementary Tables S1-S5, Figure S1 from Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium

Author: Ose, Jennifer, primary, Poole, Elizabeth M., primary, Schock, Helena, primary, Lehtinen, Matti, primary, Arslan, Alan A., primary, Zeleniuch-Jacquotte, Anne, primary, Visvanathan, Kala, primary, Helzlsouer, Kathy, primary, Buring, Julie E., primary, Lee, I-Min, primary, Tjønneland, Anne, primary, Dossus, Laure, primary, Trichopoulou, Antonia, primary, Masala, Giovanna, primary, Onland-Moret, N. Charlotte, primary, Weiderpass, Elisabete, primary, Duell, Eric J., primary, Idahl, Annika, primary, Travis, Ruth C., primary, Rinaldi, Sabina, primary, Merritt, Melissa A., primary, Trabert, Britton, primary, Wentzensen, Nicolas, primary, Tworoger, Shelley S., primary, Kaaks, Rudolf, primary, and Fortner, Renée T., primary
Published: 2023
Full Text: View/download PDF

47. Supplementary Data from Circulating Immune Cell Composition and Cancer Risk: A Prospective Study Using Epigenetic Cell Count Measures

Author: Le Cornet, Charlotte, primary, Schildknecht, Konstantin, primary, Rossello Chornet, Araceli, primary, Fortner, Renée T., primary, González Maldonado, Sandra, primary, Katzke, Verena A., primary, Kühn, Tilman, primary, Johnson, Theron, primary, Olek, Sven, primary, and Kaaks, Rudolf, primary
Published: 2023
Full Text: View/download PDF

48. Supplemental Table 1 from Human Chorionic Gonadotropin Does Not Correlate with Risk for Maternal Breast Cancer: Results from the Finnish Maternity Cohort

Author: Fortner, Renée T., primary, Schock, Helena, primary, Kaaks, Rudolf, primary, Lehtinen, Matti, primary, Pukkala, Eero, primary, Lakso, Hans-Åke, primary, Tanner, Minna, primary, Kallio, Raija, primary, Joensuu, Heikki, primary, Korpela, Jaana, primary, Toriola, Adetunji T., primary, Hallmans, Göran, primary, Grankvist, Kjell, primary, Zeleniuch-Jacquotte, Anne, primary, Toniolo, Paolo, primary, Lundin, Eva, primary, and Surcel, Heljä-Marja, primary
Published: 2023
Full Text: View/download PDF

49. Data from Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium

Author: Ose, Jennifer, primary, Poole, Elizabeth M., primary, Schock, Helena, primary, Lehtinen, Matti, primary, Arslan, Alan A., primary, Zeleniuch-Jacquotte, Anne, primary, Visvanathan, Kala, primary, Helzlsouer, Kathy, primary, Buring, Julie E., primary, Lee, I-Min, primary, Tjønneland, Anne, primary, Dossus, Laure, primary, Trichopoulou, Antonia, primary, Masala, Giovanna, primary, Onland-Moret, N. Charlotte, primary, Weiderpass, Elisabete, primary, Duell, Eric J., primary, Idahl, Annika, primary, Travis, Ruth C., primary, Rinaldi, Sabina, primary, Merritt, Melissa A., primary, Trabert, Britton, primary, Wentzensen, Nicolas, primary, Tworoger, Shelley S., primary, Kaaks, Rudolf, primary, and Fortner, Renée T., primary
Published: 2023
Full Text: View/download PDF

50. Data from Circulating Immune Cell Composition and Cancer Risk: A Prospective Study Using Epigenetic Cell Count Measures

Author: Le Cornet, Charlotte, primary, Schildknecht, Konstantin, primary, Rossello Chornet, Araceli, primary, Fortner, Renée T., primary, González Maldonado, Sandra, primary, Katzke, Verena A., primary, Kühn, Tilman, primary, Johnson, Theron, primary, Olek, Sven, primary, and Kaaks, Rudolf, primary
Published: 2023
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

476 results on '"Fortner, Renée T."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources